Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

108 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition.
Goudar RK, Shi Q, Hjelmeland MD, Keir ST, McLendon RE, Wikstrand CJ, Reese ED, Conrad CA, Traxler P, Lane HA, Reardon DA, Cavenee WK, Wang XF, Bigner DD, Friedman HS, Rich JN. Goudar RK, et al. Among authors: wikstrand cj. Mol Cancer Ther. 2005 Jan;4(1):101-12. Mol Cancer Ther. 2005. PMID: 15657358
Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.
Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE 2nd, Cokgor I, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Regalado LV, Sampson JH, Shafman TD, Wikstrand CJ, Wong TZ, Zhao XG, Zalutsky MR, Bigner DD. Reardon DA, et al. Among authors: wikstrand cj. J Clin Oncol. 2002 Mar 1;20(5):1389-97. doi: 10.1200/JCO.2002.20.5.1389. J Clin Oncol. 2002. PMID: 11870184 Clinical Trial.
Phase II trial of gefitinib in recurrent glioblastoma.
Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, Wikstrand CJ, Van Duyn LB, Dancey JE, McLendon RE, Kao JC, Stenzel TT, Ahmed Rasheed BK, Tourt-Uhlig SE, Herndon JE 2nd, Vredenburgh JJ, Sampson JH, Friedman AH, Bigner DD, Friedman HS. Rich JN, et al. Among authors: wikstrand cj. J Clin Oncol. 2004 Jan 1;22(1):133-42. doi: 10.1200/JCO.2004.08.110. Epub 2003 Nov 24. J Clin Oncol. 2004. PMID: 14638850 Clinical Trial.
MRP3: a molecular target for human glioblastoma multiforme immunotherapy.
Kuan CT, Wakiya K, Herndon JE 2nd, Lipp ES, Pegram CN, Riggins GJ, Rasheed A, Szafranski SE, McLendon RE, Wikstrand CJ, Bigner DD. Kuan CT, et al. Among authors: wikstrand cj. BMC Cancer. 2010 Sep 1;10:468. doi: 10.1186/1471-2407-10-468. BMC Cancer. 2010. PMID: 20809959 Free PMC article.
Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors.
Zalutsky MR, Boskovitz A, Kuan CT, Pegram CN, Ayriss J, Wikstrand CJ, Buckley AF, Lipp ES, Herndon JE 2nd, McLendon RE, Bigner DD. Zalutsky MR, et al. Among authors: wikstrand cj. Nucl Med Biol. 2012 Jan;39(1):23-34. doi: 10.1016/j.nucmedbio.2011.06.005. Epub 2011 Sep 29. Nucl Med Biol. 2012. PMID: 21958852 Free PMC article.
108 results